Additionally, the study primarily relies on in vitro cell experiments, necessitating validation through in vivo animal studies to enhance the comprehensive understanding of the therapeutic mechanisms of the PI3K/Akt pathway in RCC treatment and establish a robust foundation for clinical translation. This evidence concerns the gene AKT1 and renal cell carcinoma.